BioMarin enters $600M revolving credit facility maturing 2029, undrawn at closing

BIOMARIN PHARMACEUTICAL INC

Entered $600M revolving credit facility with Citibank as administrative agent.
Facility matures on August 28, 2029; no amounts drawn at closing.
Interest: Term SOFR plus 112.5-175 bps or Base Rate plus 12.5-75 bps, based on leverage.
Proceeds to finance working capital and general corporate purposes.
Includes customary covenants restricting debt, liens, investments, and dividends.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.